Prof Ulrich Jäger

Main interest

Prof Jäger holds a medical university degree and is specifically trained in hematology and oncology. He is mainly interested in the molecular biology of leukemias and lymphomas.

 

Research interests:

  • Molecular hematology
  • Molecular biology of leukemias and lymphomas
  • Minimal Residual Disease (MRD)
  • Molecular mechanism of chromosomal translocation
  • Chronic Lymphocytic Leukemia (CLL)

 

Current position

He is professor of hematology and head of the division of hematology and hemostaseology at the Medical University of Vienna.

Education

After Prof Ulrich Jäger obtained a university degree in General Internal Medicine of the University of Vienna with specific specialization in hematology/oncology, he gained further experience in this field performing several scientific projects. At the Washington University, under the supervision of Prof Korsmeyer, he was mainly interested in the molecular biology of lymphomas. As the group leader of the division of hematology at the University of Vienna, he took part in numerous scientific projects concerning the molecular biology of leukemias and lymphomas and the mechanism of chromosoal translocations, and he performed several clinical studies in Minimal Residual Disease (MRD) in lymphomas and leukemias.

Other activities

He is a member of the Austrian Society of Hematology and Oncology and the Austrian Society of Medicine as well as a member of the American and the European Society of Hematology.

Prof Jäger is actively involved in the strategy commission of the German CLL Study Group, the protocol committee of the German indolent NHL Study Group, and he is president of the European Haematology Association.

He is editor of the Educational series of the Wiener Klinische Wochenschrift and section editor of Annals of Hematology.

Prof Jäger has published numerous publications and review articles, acts as a reviewer for international journals and has been awarded several times; in 2010 he gained the Sanofi Aventis Award.

Last update: 2011-07-24

The content of this website is intended for healthcare professionals.
All content is approved by the INC-EU study group members.

The INC-EU and this website are supported by an educational grant from

Amgen (Europe) GmbH.